GenScript Executive and Leadership Team

Patrick Liu, the Acting Chief Executive Officer, ProBio at GenScript, directs the strategic trajectory of the biologics contract development and manufacturing organization platform. Overseeing complex manufacturing workflows, the Acting Chief Executive Officer, ProBio ensures that global research partners receive high-quality, scalable solutions for drug development. This leadership role involves managing cross-functional teams to optimize production efficiency and accelerate time-to-market for critical therapeutic candidates. By aligning technical capabilities with market demands, Patrick Liu drives the expansion of the CDMO platform across international markets. The Acting Chief Executive Officer, ProBio maintains rigorous quality standards while fostering innovation in synthetic biology. Through constant evaluation of operational performance, the Acting Chief Executive Officer, ProBio secures the competitive position of the organization within the global biotech landscape, ensuring that all manufacturing initiatives support the broader mission of advancing life sciences research.

Phil Zhou, the Chief Financial Officer at GenScript, manages the fiscal health and capital allocation strategies for the entire enterprise. Overseeing global financial reporting, the Chief Financial Officer ensures transparency and compliance across all four business platforms, including the integrated cell therapy and industrial synthetic products divisions. This leadership role involves coordinating with the Board to optimize resource distribution and support long-term growth objectives. By implementing robust financial controls, Phil Zhou drives operational efficiency and mitigates risks associated with international market volatility. The Chief Financial Officer monitors capital expenditures to ensure alignment with the company's research-focused mission. Through strategic financial planning, the Chief Financial Officer strengthens the balance sheet, enabling sustained investment in cutting-edge biotechnology. Ultimately, the Chief Financial Officer provides the necessary fiscal foundation to support the company's role as a leading provider of life sciences services and products.

Josie Zhou, the Interim Chief Financial Officer & Vice President, Finance at GenScript, executes financial oversight and manages internal accounting operations. Overseeing the daily financial functions, the Interim Chief Financial Officer & Vice President, Finance ensures accurate reporting and budgetary discipline across the life-science services and products platform. This leadership role involves collaborating with department heads to streamline cost structures and improve profit margins. By analyzing fiscal data, Josie Zhou drives informed decision-making that supports the company's expansion into new research markets. The Interim Chief Financial Officer & Vice President, Finance maintains rigorous internal controls to safeguard assets and ensure regulatory adherence. Through meticulous management of financial workflows, the Interim Chief Financial Officer & Vice President, Finance supports the overall stability of the organization. This role remains critical in maintaining the financial agility required to sustain the company's position as a global leader in biotechnology.

Patrick L., the President, Biosciences Group at GenScript, directs the development and delivery of life-science services and products for global research communities. Overseeing the research and development pipeline, the President, Biosciences Group ensures that the company provides one-stop solutions for complex scientific challenges. This leadership role involves managing product innovation and ensuring that the Biosciences Group meets the evolving needs of academic and commercial laboratories. By driving advancements in synthetic biology, Patrick L. enhances the company's market impact and scientific reputation. The President, Biosciences Group coordinates with other C-suite leaders to integrate these services into the broader corporate strategy. Through the optimization of research workflows, the President, Biosciences Group supports the acceleration of discovery processes for clients worldwide. This leadership role focuses on maintaining high standards of quality and reliability, ensuring that the Biosciences Group remains at the forefront of the global life sciences industry.

Sally Wang, the President at GenScript, oversees the overarching operational strategy and coordinates the integration of the company's four primary platforms. Directing the alignment of the life-science services, CDMO, industrial synthetic products, and cell therapy divisions, the President ensures that the organization functions as a cohesive unit. This leadership role involves managing high-level corporate initiatives and fostering collaboration across all business units to drive sustainable growth. By setting strategic priorities, Sally Wang ensures that the company maintains its status as a global leader in biotechnology. The President monitors market trends to identify new opportunities for expansion and innovation. Through effective leadership, the President supports the development of integrated solutions that address the needs of the global research community. This role requires constant engagement with the Board and executive team to ensure that all operational activities remain consistent with the company's mission of advancing life sciences through superior technology and service.

Janice Jin, the Division President, , Life Science Group, Genscript (APAC) at GenScript, directs all life science operations and market expansion efforts across the Asia-Pacific region. Overseeing regional sales and service delivery, the Division President, , Life Science Group, Genscript (APAC) ensures that the company's life-science services and products reach diverse research communities effectively. This leadership role involves tailoring the company's one-stop solutions to meet the specific regulatory and scientific requirements of the APAC market. By driving regional growth, Janice Jin strengthens the company's global footprint and enhances its competitive edge. The Division President, , Life Science Group, Genscript (APAC) collaborates with global leadership to ensure that regional strategies align with the broader corporate mission. Through the management of local teams and resources, the Division President, , Life Science Group, Genscript (APAC) fosters innovation and maintains high service standards, ensuring that the company remains the preferred partner for research institutions throughout the region.

Luquan Wang, the Executive Director and President at GenScript, architects the long-term vision and governance framework for the organization. Overseeing the strategic direction of the integrated global cell therapy platform, the Executive Director and President ensures that the company remains at the cutting edge of therapeutic innovation. This leadership role involves guiding the Board and executive team through complex decision-making processes to maintain the company's market leadership. By focusing on high-impact research and development, Luquan Wang drives the advancement of next-generation medical solutions. The Executive Director and President coordinates with other leaders to ensure that all business platforms, including the CDMO and industrial synthetic products, support the company's core mission. Through rigorous oversight and strategic planning, the Executive Director and President secures the company's future growth and maintains its reputation as a premier provider of life sciences services and products on a global scale.